EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1 ‐rearranged porocarcinoma

Mélanie Legrand iD, Baptiste Louveau iD, Amélie Osio iD, Anne Tallet iD, Eduardo Calonje iD, Jean-Yves Scoazec iD, Arnaud de la Fouchardiere iD, Franck Tirode iD, Andreas Von Deimling iD, Klaus Busam iD, Ahmed Shah iD, Ashley Flaman iD und 14 weitere

Histopathology · 2025

DOI: 10.1111/his.15444 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Histopathology, 2025. Verfasst von Mélanie Legrand und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France. Hauptthemen laut MEDLINE: Nuclear Proteins, Skin Neoplasms, Neoplasm Proteins, Eccrine Porocarcinoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Illumina grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NUT carcinoma is a rare malignant neoplasm characterised by recurrent NUTM1 rearrangements, initially reported in the midline. Recently, 10 cases of cutaneous NUT carcinoma with adnexal differentiation harbouring BRD3::NUTM1 , NSD3::NUTM1 , BRD4::NUTM1 or BRD3::NUTM2B fusions have been reported. Accordingly, ‘NUT adnexal carcinoma’ (NAC) has been introduced as a provisional tumour entity to the fifth edition of the WHO Classification of Skin Tumours.

Aims

We report the histopathological, molecular genetic and epigenetic features of seven additional cases of NAC. Methods and results The cohort consisted of four female and three male patients with a median age of 58 years. Follow‐up was available for six cases, and documented diffuse metastatic spreading leading to death at 18 months after diagnosis for one case. Histopathological examination in all cases revealed dermal/subcutaneous neoplasms composed of poorly differentiated cells with large irregular vesicular nuclei and at least focally prominent nucleoli. All cases showed areas of duct/gland formation. Using immunohistochemistry, all tumours showed diffuse NUT expression with co‐expression of SOX10 in five cases. P63 and P40 were diffusely positive in one case and confined to the periphery of the tumour nests in five cases. Molecular analysis showed BRD4::NUTM1 fusions ( n = 3), BRD3::NUTM1 fusions ( n = 3) and NSD3::NUTM1 ( n = 1). Although being close to this latter group, methylation and transcriptional analysis revealed that NAC formed a unique cluster distinct from extracutaneous NUT carcinoma and NUTM1 ‐rearranged porocarcinoma.

Conclusions

Our results further support the existence of primary cutaneous NAC and suggest that it may represent an entity distinct from extracutaneous NUT carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear ProteinsSkin NeoplasmsNeoplasm ProteinsEccrine PorocarcinomaSweat Gland NeoplasmsCarcinomaHumansFemaleMaleMiddle AgedAgedDNA MethylationAdultGene RearrangementOncogene Proteins, Fusion

Stichwörter der Autor:innen

BRD4NUTNUTM1SOX10carcinomaskin

Substanzen

NUTM1 protein, humanNuclear ProteinsNeoplasm ProteinsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Pathology, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France.
  • Université Paris Cité, Paris, France.
  • INSERM U976, Institut de Recherche Saint-Louis, Paris, France.
  • Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Department of Pathology, APHP Hôpital Saint Louis, Université Paris Cité, Paris, France.
  • CND Paris-La Roquette, Paris, France.

ORCID-Profile: Mélanie Legrand, Baptiste Louveau, Amélie Osio, Anne Tallet, Eduardo Calonje, Jean-Yves Scoazec, Arnaud de la Fouchardiere, Franck Tirode, Andreas Von Deimling, Klaus Busam, Ahmed Shah, Ashley Flaman, Fanélie Jouenne, Samia Mourah, Daniel Pissaloux, Sylvie Lantuejoul, Christopher A French, Keisuke Goto, Bernard Cribier, Carina A Dehner, Ahmed K Alomari, Christopher Dm Fletcher, John Hanna, Nicolas Macagno, Maxime Battistella, Thibault Kervarrec

Förderung

  • NCI NIH HHS
  • Illumina grant

Zitieren

APA

Legrand, M., Louveau, B., Osio, A., Tallet, A., Calonje, E., Scoazec, J. Y., de la Fouchardiere, A., Tirode, F., Von Deimling, A., Busam, K., Shah, A., Flaman, A., Jouenne, F., Mourah, S., Pissaloux, D., Lantuejoul, S., French, C. A., Goto, K., Cribier, B., …, & Kervarrec, T. (2025). Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1 ‐rearranged porocarcinoma. Histopathology. https://doi.org/10.1111/his.15444

Vancouver

Legrand M, Louveau B, Osio A, Tallet A, Calonje E, Scoazec JY, et al. Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1 ‐rearranged porocarcinoma. Histopathology. 2025. doi:10.1111/his.15444

BibTeX
@article{Legrand2025,
  author = {Legrand, Mélanie and Louveau, Baptiste and Osio, Amélie and Tallet, Anne and Calonje, Eduardo and Scoazec, Jean-Yves and de la Fouchardiere, Arnaud and Tirode, Franck and Von Deimling, Andreas and Busam, Klaus and Shah, Ahmed and Flaman, Ashley and Jouenne, Fanélie and Mourah, Samia and Pissaloux, Daniel and Lantuejoul, Sylvie and French, Christopher A and Goto, Keisuke and Cribier, Bernard and Dehner, Carina A and Alomari, Ahmed K and Fletcher, Christopher Dm and Hanna, John and Macagno, Nicolas and Battistella, Maxime and Kervarrec, Thibault},
  title = {Primary cutaneous NUT adnexal carcinoma: morphologic, genetic and methylation analysis of seven new cases with comparison to extracutaneous NUT carcinoma and NUTM1 ‐rearranged porocarcinoma},
  journal = {Histopathology},
  year = {2025},
  doi = {10.1111/his.15444}
}
Kostenlos starten →